{Reference Type}: Journal Article
{Title}: What is the association of preoperative biopsy with recurrence and survival in retroperitoneal sarcoma? A systematic review by the Australia and New Zealand Sarcoma Association clinical practice guidelines working party.
{Author}: Webster S;Vargas AC;Maclean F;Vu J;Tong E;Coker D;Ward I;Connolly EA;Zhou DD;Mar J;Lazarakis S;Gyorki DE;Hong AM;
{Journal}: Crit Rev Oncol Hematol
{Volume}: 197
{Issue}: 0
{Year}: 2024 May 13
{Factor}: 6.625
{DOI}: 10.1016/j.critrevonc.2024.104354
{Abstract}: Preoperative biopsy for retroperitoneal sarcoma (RPS) enables appropriate multidisciplinary treatment planning. A systematic review of literature from 1990 to June 2022 was conducted using the population, intervention, comparison and outcome model to evaluate the local recurrence and overall survival of preoperative biopsy compared to those that had not. Of 3192 studies screened, five retrospective cohort studies were identified. Three reported on biopsy needle tract seeding, with only one study reporting biopsy site recurrence of 2 %. Two found no significant difference in local recurrence and one found higher 5-year local recurrence rates in those who had not been biopsied. Three studies reported overall survival, including one with propensity matching, did not show a difference in overall survival. In conclusion, preoperative core needle biopsy of RPS is not associated with increased local recurrence or adverse survival outcomes.